×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

VBI Vaccines Stock Forecast, Price & News

$0.82
+0.01 (+1.22%)
(As of 07/5/2022 05:46 PM ET)
Add
Compare
Today's Range
$0.78
$0.84
50-Day Range
$0.66
$1.35
52-Week Range
$0.64
$3.81
Volume
1.24 million shs
Average Volume
3.67 million shs
Market Capitalization
$211.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

VBI Vaccines MarketRank™ Forecast

Analyst Rating
Strong Buy
3.50 Rating Score
Upside/​Downside
633.2% Upside
$6.00 Price Target
Short Interest
Bearish
8.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.27) to ($0.21) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.19 out of 5 stars

Medical Sector

282nd out of 1,426 stocks

Pharmaceutical Preparations Industry

130th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBI Vaccines logo

About VBI Vaccines (NASDAQ:VBIV) Stock

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

VBIV Stock News Headlines

VBI Vaccines launches Hepatitis B vaccine in U.S.
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBIV
Fax
N/A
Employees
149
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/06/2022
Next Earnings (Estimated)
8/01/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+633.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.5
Research Coverage
2 Analysts

Profitability

Net Income
$-69,750,000.00
Net Margins
-16,087.72%
Pretax Margin
-16,087.72%

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
$0.56 per share

Miscellaneous

Free Float
237,596,000
Market Cap
$211.33 million
Optionable
Optionable
Beta
1.98














VBI Vaccines Frequently Asked Questions

Should I buy or sell VBI Vaccines stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" VBI Vaccines stock.
View analyst ratings for VBI Vaccines
or view top-rated stocks.

What is VBI Vaccines' stock price forecast for 2022?

2 analysts have issued twelve-month price objectives for VBI Vaccines' stock. Their VBIV stock forecasts range from $6.00 to $6.00. On average, they predict VBI Vaccines' stock price to reach $6.00 in the next year. This suggests a possible upside of 633.2% from the stock's current price.
View analysts' price targets for VBI Vaccines
or view top-rated stocks among Wall Street analysts.

How has VBI Vaccines' stock performed in 2022?

VBI Vaccines' stock was trading at $2.34 at the beginning of 2022. Since then, VBIV stock has decreased by 65.0% and is now trading at $0.8183.
View the best growth stocks for 2022 here
.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for VBI Vaccines
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) released its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.13 million. VBI Vaccines had a negative net margin of 16,087.72% and a negative trailing twelve-month return on equity of 48.77%.
View VBI Vaccines' earnings history
.

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Mr. Jeffery R. Baxter F.C.M.A., FCMA, Pres, CEO & Director (Age 61, Pay $1.04M)
  • Mr. Christopher McNulty, CFO, Head of Bus. Devel. & Director (Age 45)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 52, Pay $605.07k)
  • Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D., Chief Medical Officer (Age 67, Pay $652.09k)
  • Nicole Anderson, Director of Corp. Communications & Investor Relations
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 57)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 34) (LinkedIn Profile)
  • Mr. Avi Mazaltov, Global Head of Manufacturing & GM of SciVac (Age 60)
  • Mr. Misha Nossov, Sr. VP of Market Access & Commercial
  • Mr. T. Adam Buckley, Sr. VP of Bus. Devel. (Age 46)

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $0.82.

How much money does VBI Vaccines make?

VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $211.33 million and generates $630,000.00 in revenue each year. The biopharmaceutical company earns $-69,750,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How many employees does VBI Vaccines have?

VBI Vaccines employs 149 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for VBI Vaccines is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com.

This page (NASDAQ:VBIV) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.